Result of AGM

By

Regulatory News | 18 Jun, 2024

Updated : 16:55

RNS Number : 9362S
Intelligent Ultrasound Group PLC
18 June 2024
 

Intelligent Ultrasound Group plc

("Intelligent Ultrasound" or the "Group" or the "Company")

 

Result of AGM

 

Intelligent Ultrasound Group plc (AIM: IUG), the 'classroom to clinic' ultrasound company, specialising in artificial intelligence (AI) software and simulation, announces that at the AGM held earlier today, all resolutions were duly passed.

 

The voting results are displayed below.

 

Resolution

For

For %

Discretion

Against

Against %

Withheld

1

190,558,104

100.00

20,000

0

0.00

31,123

2

190,557,660

100.00

20,000

0

0.00

31,567

3

160,032,945

85.45

20,000

27,265,930

14.56

3,290,352

4

190,586,977

99.98

20,000

2,250

0.01

0

5

190,586,533

99.98

20,000

2,250

0.01

444

6

190,586,533

99.99

20,000

2,250

0.01

444

7

190,555,410

99.99

20,000

2,250

0.01

31,567

8

160,032,945

85.44

20,000

27,265,486

14.56

3,290,796

9

190,555,854

99.97

20,000

33,373

0.02

0

10

190,555,854

99.98

20,000

33,373

0.02

0

11

190,555,410

99.98

20,000

33,373

0.02

444

12

190,324,838

99.86

20,000

264,389

0.14

0

13

190,311,204

99.86

20,000

271,579

0.14

6,444

 

 

For further information, please contact:

 

 

Intelligent Ultrasound Group plc

www.intelligentultrasound.com

Stuart Gall, CEO

Tel: +44 (0)29 2075 6534

Helen Jones, CFO

 


 

Cavendish Capital Markets Limited

(Nominated advisor and broker)

 

Giles Balleny (Corporate Finance)

Nigel Birks (ECM)

Dale Bellis (Sales)

Tel: +44 (0)20 7397 8900

 

 


 

 TB Cardew - PR Advisors

 Ed Orlebar

Intelligentultrasound@tbcardew.com

          Tel: +44 (0)7738 724630

 Allison Connolly

Tel: +44 (0)7587 453955

 Emma Pascoe-Watson

Tel: +44 (0)7774 620415

 Jessica Pilling

Tel: +44 (0)7918 584573

 

 

About Intelligent Ultrasound Group

Intelligent Ultrasound (AIM: IUG) is one of the world's leading 'classroom to clinic' ultrasound companies, specialising in real-time hi-fidelity virtual reality simulation for the ultrasound training market ('classroom') and artificial intelligence-based clinical image analysis software tools for the diagnostic medical ultrasound market ('clinic'). Based in Cardiff in the UK and Atlanta in the US, the Group has two revenue streams:

 

Simulation

Real-time hi-fidelity ultrasound education and training through simulation.  Our main products are the ScanTrainer obstetrics and gynaecology training simulator, the HeartWorks echocardiography training simulator, the BodyWorks Eve Point of Care and Emergency Medicine training simulator with Covid-19 module and the new BabyWorks Neonate and Paediatric training simulator. To date over 1,700 simulators have been sold to over 800 medical institutions around the world.

 

Clinical AI software

Deep learning-based algorithms to make ultrasound machines smarter and more accessible using our proprietary ScanNav ultrasound image analysis technology. Current products on the market utilising this technology are GE HealthCare's SonoLyst software that is incorporated in their Voluson Expert and SWIFT ultrasound machines; ScanNav Anatomy PNB that simplifies ultrasound-guided needling by providing the user with real-time AI-based anatomy highlighting for a range of medical procedures; and NeedleTrainer that teaches real-time ultrasound-guided needling and incorporates ScanNav Anatomy PNB. 

 

www.intelligentultrasound.com

 

NOTE: ScanNav Anatomy PNB is CE approved and cleared for sale in the US by the FDA but is not available for sale in any other territory requiring government approval for this type of product.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGSFEFIAELSEIM

Last news